S. Jay Mathews, MD

Reflow Medical Spur Stent System Granted FDA De Novo Clearance

May 29, 2025—Reflow Medical, Inc. announced that the FDA has granted de novo clearance for the company’s Spur peripheral retrievable stent system for the treatment of de novo or restenotic lesions after predilatation in patients with infrapopliteal arterial disease.

Cagent Initiates POINT FORCE Registry of Serranator PTA Catheter

January 28, 2025—Cagent Vascular, Inc., a developer of serration technology for vessel dilation in endovascular interventions, announced the start of the POINT FORCE registry, a postmarket clinical follow-up study of the company’s Serranator percutaneous transluminal angioplasty serration balloon catheter.

Reflow Spur’s DEEPER REVEAL Trial Completes Enrollment

May 8, 2024—Reflow Medical, Inc. announced the completion of enrollment in the DEEPER REVEAL clinical trial of the Reflow Spur.

Akura’s Mechanical Thrombectomy Platform Used in FIH Study for VTE

May 10, 2023—Akura Medical, a privately held portfolio company of Shifamed LLC, announced it has initiated its first-in-human clinical study of the Akura mechanical thrombectomy platform.

RapidAI Launches Rapid Workflow for PE App Developed With Penumbra

June 24, 2021—RapidAI announced the availability of a mobile and web-based app designed to align hospital teams on the treatment of patients suspected of having a pulmonary embolism (PE).

Reflow Medical Introduces Spex LP Shapeable Reinforced Support Catheter

January 13, 2021—Reflow Medical, Inc. announced the introduction of the company’s low-profile Spex LP 0.014 and 0.018-inch reinforced support catheters.

Intact Vascular's Tack Endovascular System (4F) for BTK Arteries Introduced in the United States

April 22, 2020—Intact Vascular, Inc. announced the launch of its Tack endovascular system (4F) with the first commercial use of the device at multiple sites across the United States.

FDA Clears Expanded Indication for Reflow Medical’s Wingman Catheter to Cross Peripheral CTOs

March 3, 2020—Reflow Medical, Inc. announced FDA clearance for an expanded indication for the Wingman crossing catheter after completing the Wing-IT clinical trial.

Third-Party Evaluation Confirms Safety Profile of Philips' Stellarex 0.035-Inch, Low-Dose, Paclitaxel-Based DCB

October 1, 2019—Royal Philips announced results from third-party analyses of patient-level data from worldwide clinical trials of the company’s paclitaxel-based Stellarex .035-inch, low-dose, drug-coated balloon (DCB).

Three-Year Data Support Safety and Efficacy of the Philips Stellarex DCB

May 29, 2019—Royal Philips announced that the 3-year results from the ILLUMENATE pivotal trial and the ILLUMENATE European randomized clinical trial (EU RCT) were presented by S. Jay Mathews, MD, at the New Cardiovascular Horizons 20th annual conference held May 29–31 in New Orleans, Louisiana.

Wing-IT Trial Begins for Reflow Medical's Wingman Catheters to Treat Peripheral CTO Lesions

March 13, 2018—Reflow Medical, Inc. announced the start of enrollment in its prospective multicenter nonrandomized study evaluating the ability of the Wingman catheters to cross chronic total occlusions (CTOs) in peripheral lesions.